Lansoprazole enteric-coated tablet for treating gastric ulcer and preparation method thereof

A technology of lansoprazole enteric and lansoprazole, which is applied in the field of lansoprazole enteric-coated tablets, can solve the problems that the blood drug concentration cannot maintain the therapeutic level, the blood drug concentration fluctuates greatly, and it is inconvenient for patients to take it. Simple, stable release, solve the effect of uneven mixing

Inactive Publication Date: 2016-08-24
NANJING HUAKUANG INFORMATION CONSULTING CENT
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Lansoprazole enteric-coated tablets currently used clinically are highly irritating to the stomach, and the blood drug concentration cannot maintain the therapeutic level. There are disadvantages such as inconvenience for patients to take, easy to forget to take or miss doses, and large fluctuations in blood drug concentration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lansoprazole enteric-coated tablet for treating gastric ulcer and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Weigh 50 parts of lansoprazole, 15 parts of anhydrous calcium hydrogen phosphate, 20 parts of polyvinylpyrrolidone, 5 parts of magnesium stearate, 10 parts of cross-linked hydroxymethyl cellulose; 8 parts of acrylic resin No. Ⅱ, acrylic acid Resin No. 12 parts.

[0019] Preparation Process:

[0020] (1) dissolving polyvinylpyrrolidone in ethanol solution to prepare alcoholic solution; (2) lansoprazole after sieving, remaining polyvinylpyrrolidone, L-alanine, alginic acid and lactose in Fully mix in a particle mixer, add the above-mentioned alcohol solution of polyvinylpyrrolidone, and mix thoroughly to obtain a soft material; (3) After drying the above-mentioned soft material, add magnesium stearate to obtain a mixed powder, and all the mixed powder is added to the multi-directional movement Mixer, use rotary lozenge machine tablet, make plain tablet; (4) preparation of coating solution: talcum powder is sieved and mixed, add in the ethanol solution containing sodium c...

Embodiment 5

[0034] The release research of embodiment 5 Lansoprazole enteric-coated tablets

[0035] Release test method: get the tablet prepared by Example 1 of the present invention and comparative example 2-4 respectively, according to release test method (Chinese Pharmacopoeia version two appendix XD first method in 2010), Chinese Pharmacopoeia version appendix in 2010, blue The method is 75 rev / min, and 1000ml of artificial intestinal fluid is used as the release solvent for this product. The release rate of Lansoprazole Enteric-coated Tablets was determined by UV spectrophotometry at 233nm using the absorption coefficient method.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a kind of lansoprazole enteric-coated tablet for the treatment of gastric ulcer, belongs to the technical field of western medicine preparation, is made up of plain tablet and coating, by enteric-coated tablet gross weight percentage, described plain tablet is made up of following composition: 30-70 parts of lansoprazole, 10-20 parts of anhydrous calcium hydrogen phosphate, 10-30 parts of polyvinylpyrrolidone, etc., are mixed by a specific particle mixer, and the slow release of the tablet of the present invention is stable.

Description

technical field [0001] The invention belongs to the technical field of western medicine preparations, in particular to a lansoprazole enteric-coated tablet for treating gastric ulcer. Background technique [0002] Lansoprazole tablets, indications for gastric ulcer, duodenal ulcer, reflux esophagitis, Zoller-Ellison syndrome (gastrinoma). Lansoprazole enteric-coated tablets currently used clinically are highly irritating to the stomach, and the blood drug concentration cannot maintain the therapeutic level. There are disadvantages such as inconvenience for patients to take, easy to forget to take or miss doses, and large fluctuations in blood drug concentration. Contents of the invention [0003] In order to overcome the deficiencies in the prior art, the present invention provides a lansoprazole enteric-coated tablet through a large number of tests on auxiliary material screening, process optimization and equipment improvement. The tablet is sustained-release, has small ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/32A61K31/4439A61J3/00A61P1/04A61P35/00
CPCA61K31/4439A61J3/005A61K9/2846
Inventor 李洋
Owner NANJING HUAKUANG INFORMATION CONSULTING CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap